Publications







Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
J Clin Oncol 2017 Oct 30;35(30):3433-3439. Epub 2017 Aug 30.
George D. Demetri, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium; Giovanni Grignani, Fondazione del Piemonte per l'Oncologia Istituto di Ricovero e Cura a Carattere Scientifico, Candiolo, Italy; Jean-Yves Blay, Université Claude Bernard and Centre Léon Bérard, Lyon, France; Robert G. Maki, Monter Cancer Center, Lake Success; and Cold Spring Harbor Laboratory, New Hyde Park, NY; Brian A. Van Tine, Barnes and Jewish Hospital, Washington University in St. Louis, St. Louis, MO; Thierry Alcindor, McGill University Health Centre, Montreal, Quebec, Canada; Robin L. Jones, The Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom; David R. D'Adamo and Matthew Guo, Eisai, Woodcliff Lake, NJ; and Sant Chawla, Sarcoma Oncology Center, Santa Monica, CA.







Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.
J Clin Oncol 2017 May 31;35(15):1713-1720. Epub 2017 Mar 31.
Paolo G. Casali, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori and University of Milan; Elena Fumagalli and Alessandro Gronchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Tumori, Milano, Italy; John Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park and University of Adelaide, South Australia, Australia; Axel Le Cesne, Gustave Roussy, Villejuif; Jean-Yves Blay, NetSARC and Site de Recherche Intégrée sur le Cancer de Lyon, Centre Leon Berard, Lyon; Antoine Italiano, Institut Bergonie, Bordeaux, France; Peter Reichardt, HELIOS Klinikum Berlin-Buch, Berlin; Lars H. Lindner, Klinikum der Universitaet München, München; Viktor Grünwald, School Hannover, Hannover, Germany; Ian R. Judson and Winette van der Graaf, Royal Marsden Hospital, London, United Kingdom; Patrick Schöffski, Universitaire Ziekenhuizen Leuven, Campus Gasthuisberg, Leuven; Saskia Litière and Sandrine Marreaud, European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Serge Leyvraz, University Hospital, Lausanne, Switzerland; Antonio Lopez Pousa, Hospital De La Santa Creu I Sant Pau, Barcelona, Spain; Stefan Sleijfer and Jaap Verweij, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam; Jan M. Kerst, The Netherlands Cancer Institute, Amsterdam; Pancras Hogendoorn, Leiden University Medical Center, Leiden; Winette van der Graaf, Radboud University, Medical Center Nijmegen, the Netherlands; and Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.


Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
Eur J Cancer 2017 Feb 22;72:12-19. Epub 2016 Dec 22.
Centre Léon Bérard, Department of Hematology, Université Claude Bernard Lyon 1, Lyon, France; Department of Hematology, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, Pierre-Bénite, France. Electronic address:





PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.
J Clin Oncol 2016 Sep 12. Epub 2016 Sep 12.
Christopher W. Ryan, Oregon Health & Science University, Portland, OR; Ofer Merimsky, Sackler School of Medicine, Tel-Aviv, Israel; Mark Agulnik, Northwestern University, Chicago, IL; Jean-Yves Blay, Centre Léon Bérard, Lyon; Antoine Italiano, Institut Bergonié, Bordeaux, France; Scott M. Schuetze, University of Michigan, Ann Arbor, MI; Brian A. Van Tine, Washington University in St Louis, St Louis, MO; Robin L. Jones and Ian R. Judson, The Royal Marsden Hospital, London, United Kingdom; Anthony D. Elias, University of Colorado-Denver, Aurora, CO; Edwin Choy, Massachusetts General Hospital; Jill Y. Buck and Francois Lebel, ZIOPHARM Oncology, Boston, MA; Thierry Alcindor, McGill University Health Center, Montreal, Quebec, Canada; Vicki L. Keedy, Vanderbilt University Medical Center, Nashville, TN; Damon R. Reed, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Robert N. Taub, Columbia University Medical Center; Jonathan J. Lewis, Samus Therapeutics and Molecular Ninja Group; Robert G. Maki, Mount Sinai School of Medicine, New York, NY; Xavier Garcia del Muro, Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain; and Patrick Schöffski, University Hospitals Leuven, Leuven, Belgium.






[Innovative anticancer agents reserved to hospital use and not involved in the hospital budget: Creation and evolution].
Bull Cancer 2016 Apr 29;103(4):315-7. Epub 2016 Mar 29.
Société française du cancer, hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75474 Paris cedex 10, France. Electronic address:

Aggregated adverse-events outcomes in oncology phase III reports: A systematic review.
Eur J Cancer 2016 Jan 27;52:26-32. Epub 2015 Nov 27.
Medical Oncology Department, Centre Hospitalier Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), CITOHL, F-69310, Pierre-Bénite, France; Hospices Civils de Lyon, Biostatistics Unit, F-69003, Lyon, France; CNRS UMR 5558, Biometry and Evolutionary Biology Laboratory, Health and Biostatistics Team, Villeurbanne, France. Electronic address:



Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
J Clin Oncol 2015 Dec 16;33(36):4276-83. Epub 2015 Nov 16.
Paolo G. Casali, Elena Fumagalli, and Alessandro Gronchi, Fondazione Istituto di Recovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milano; Angelo P. Dei Tos, Azienda Unità Locale Socio Sanitaria 9 Treviso, Treviso, Italy; Axel Le Cesne, Gustave Roussy, Villejuif; Antoine Italiano, Institut Bergonie, Bordeaux; Antoine Adenis, Centre Oscar Lambret, Lille; Florence Duffaud, Hôpital de La Timone, Aix-Marseille Université, Marseille; Jean-Yves Blay, Centre Leon Berard, Lyon, France; Andres Poveda Velasco, Instituto Valenciano de Oncologia, Valencia; Javier M. Broto, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Dusan Kotasek, Adelaide Cancer Centre, Kurralta Park, and University of Adelaide, Adelaide, South Australia; David Goldstein, Prince of Wales Hospital, New South Wales, Sydney; John R. Zalcberg, Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland; Peter Hohenberger, Mannheim University Medical Center, Mannheim; Jörg T. Hartmann, Christian-Albrechts University, Kiel, Germany; Ian R. Judson, Royal Marsden Hospital; Winette T.A. van der Graaf, The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, United Kingdom; Hans Gelderblom, Leiden University Medical Center, Leiden; Winette T.A. van der Graaf, Radboud University Medical Center, Nijmegen, the Netherlands; Saskia Litière, and Sandrine Marréaud, European Organisation for Research and Treatment of Cancer, Brussels, Belgium.



Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Anticancer Drugs 2015 Nov;26(10):1009-16
aDepartment of Medical Oncology, University Hospital Jean Minjoz, Besançon bFaculty of Pharmacy of Lyon cLéon Bérard Cancer Center, Lyon dGeorge François Leclerc Cancer Center, Dijon eDeparment of Radiotherapy, University Hospital Tenon, Paris fFSNB Health & Care, Paris gDepartment of Pharmacy, University Hospital Jean Minjoz, Besançon, France.



Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival.
Clin Cancer Res 2015 Sep 15;21(18):4194-200. Epub 2015 Apr 15.
Department of Pathology, INSERM U916, Bergonie Institute, Bordeaux, France. Translational Research, Bergonie Institute, Bordeaux, France.


Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial.
J Clin Oncol 2015 Sep 27;33(25):2797-802. Epub 2015 Jul 27.
Isabelle L. Ray-Coquard, Philippe A. Cassier, and Jean-Yves Blay, Centre Léon Bérard and Claude Bernard University, Lyon; Julien Domont, Olivier Mir, and Axel Le Cesne, Gustave Roussy, Villejuif; Emmanuelle Tresch-Bruneel and Stéphanie Clisant, Centre Oscar Lambret; Nicolas Penel, Centre Oscar Lambret and Lille-Nord-de-France Medical School, Lille; Emmanuelle Bompas, Centre René Gauducheau, Nantes; Sophie Piperno-Neumann, Institut Curie, Paris; Antoine Italiano, Institut Bergonié, Bordeaux; Christine Chevreau, Institut Claudius Regaud, Toulouse; Didier Cupissol, Institut de Cancérologie de Montpellier, Val d'Aurelle, Montpellier; François Bertucci, Institut Paoli Calmette, Marseille; Jacques-Olivier Bay, Centre Jean Perrin, Clermont-Ferrand; Olivier Collard, Institut de Cancérologie de la Loire Lucien Neuwirth, Saint Priest en Jarez; Esma Saada-Bouzid, Centre Antoine Lacassagne, Nice; Nicolas Isambert, Centre Georges-François Leclerc, Dijon; and Corinne Delcambre, Centre François Baclesse, Caen, France.



Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
N Engl J Med 2015 Aug;373(8):726-36
From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut Bergonié Cancer Center, Bordeaux (A.I.) - all in France; University Hospital of Cologne, Cologne (J.W.), Universitätsmedizin Mannheim, Mannheim (R.-D.H.), West German Cancer Center, University Hospital Essen, Essen (M.S.), and German Cancer Consortium, Heidelberg (M.S.) - all in Germany; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona (M.E.E.-F., J.T.), and Hospital Universitario Madrid Sanchinarro, Madrid (M.H.) - both in Spain; and F. Hoffmann-La Roche, Basel, Switzerland (S.F.L., M.M., F.S., M.L.V.).

Treating metastatic sarcomas locally: a paradoxe, a rationale, an evidence?
Crit Rev Oncol Hematol 2015 Jul 13;95(1):62-77. Epub 2015 Jan 13.
Centre Antoine Lacassagne, Département d'oncologie, Département de radiothérapie, 227, Avenue de la Lanterne, 06200 Nice, France. Electronic address:

Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.
Anticancer Drugs 2015 Jul;26(6):678-81
aAdult Mesenchymal Tumor Medical Oncology Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan bDepartment of Oncology, General Hospital of Agrigento, Agrigento cDepartment of Oncology, Ospedale Civile SS Annunziata Sassari, Sassari dMedical Oncology Unit, University Hospital S. Chiara, Pisa eDepartment of Anatomic Pathology, General Hospital of Treviso, Treviso, Italy fDepartment of Oncology, University College of London Hospital gSarcoma Unit, Royal Marsden, London, UK hCentre Leon Berard, Lyon iInstitut Gustave Roussy, Villejuif, France.

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.
Oncologist 2015 Jul 12;20(7):823-30. Epub 2015 Jun 12.
Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York, USA; Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA; Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain; National Cancer Center Hospital East, Department of Surgery, Kashiwa, Japan; HELIOS Klinikum Berlin-Buch, Interdisciplinary Oncology, Berlin, Germany; General Medical Oncology, Leuven Cancer Institute, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium; University of Miami Sylvester Cancer Center, Sarcoma Medical Oncology Program, Miami, Florida, USA.


Cancer screening in France: third edition of the EDIFICE survey.
Eur J Cancer Prev 2015 Jun;24 Suppl:S68-72
aCoordination Center for Cancer Screening, Bretonneau University Hospital, Tours bDepartment of Oncology and Hematology, Paul-Brousse University Hospital, Inserm U1004, Villejuif cKantar Health, Montrouge dPorte de Saint-Cloud Clinic, Boulogne-Billancourt eRoche, Boulogne-Billancourt fLéon Bérard Cancer Centre, Lyon gDepartment of Medical Oncology, Jean Minjoz University Hospital, Besançon hCancer Control Department, Paoli-Calmettes Institute iAix Marseille University, UMR_S912, IRD jINSERM, UMR912 (SESSTIM), Marseille, France.

Breast cancer screening controversy: too much or not enough?
Eur J Cancer Prev 2015 Jun;24 Suppl:S73-6
aDepartment of Medical Oncology, Jean Minjoz University Hospital, Inserm U645, Besançon bCoordination Center for Cancer Screening, Bretonneau University Hospital, Tours cKantar Health, Montrouge dDepartment of Oncology and Hematology, Paul-Brousse University Hospital, Inserm U1004, Villejuif eLéon Bérard Cancer Centre, Lyon fPorte de Saint-Cloud Clinic, Boulogne-Billancourt gRoche, Boulogne-Billancourt hCancer Control Department, Paoli-Calmettes Institute iAix Marseille University, UMR_S912, IRD jINSERM, UMR912 (SESSTIM), Marseille, France.

Social stratification, risk factor prevalence and cancer screening attendance.
Eur J Cancer Prev 2015 Jun;24 Suppl:S77-81
aCancer Control Department, Paoli-Calmettes Institute bAix Marseille University, UMR_S912, IRD cINSERM, UMR912 (SESSTIM), Marseille dCoordination Center for Cancer Screening, Bretonneau University Hospital, Tours eKantar Health, Montrouge fPorte de Saint-Cloud Clinic, Boulogne-Billancourt gRoche, Boulogne-Billancourt hDepartment of Medical Oncology, Jean Minjoz University Hospital, Inserm U645, Besançon iLéon Bérard Cancer Centre, Lyon jDepartment of Oncology and Hematology, Paul-Brousse University Hospital, Inserm U1004, Villejuif, France.

Lung cancer risks, beliefs and healthcare access among the underprivileged.
Eur J Cancer Prev 2015 Jun;24 Suppl:S82-6
aDepartment of Oncology and Hematology, Paul-Brousse University Hospital, Inserm U1004, Villejuif bCoordination Center for Cancer Screening, Bretonneau 2 University Hospital, Tours cKantar Health, Montrouge dDepartment of Medical Oncology, Jean Minjoz University Hospital, Inserm U645, Besançon eLéon Bérard Cancer Centre, Lyon fPorte de Saint-Cloud Clinic, Boulogne-Billancourt gRoche, Boulogne Billancourt hDepartment of Cancer Control, Paoli-Calmettes Institute iAix Marseille University, UMR_S912, IRD jINSERM, UMR912 (SESSTIM), Marseille, France.






Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting.
J Thorac Oncol 2015 Feb;10(2):309-15
*Respiratory Medicine Service, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France; †Respiratory Medicine Service, Hôpital Larrey, CHU de Toulouse, Université de Toulouse III (Paul Sabatier), Toulouse, France; ‡Department of Medicine, Leon Bérard Cancer Center, Lyon, France; §Pathology Department, Hospices Civils de Lyon, Lyon, France; ║Thoracic Surgery Department, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France; and ¶Respiratory Medicine Department, Percy Military Hospital, Clamart, France.


Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response.
Stem Cell Reports 2015 Feb 15;4(2):239-54. Epub 2015 Jan 15.
CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France; Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France; Université de Lyon, 69000 Lyon, France; Department of Immunity, Virus, and Microenvironment, 69000 Lyon, France; Université de Lyon 1, ISPB, 69000 Lyon, France. Electronic address:


Classification of current anticancer immunotherapies.
Oncotarget 2014 Dec;5(24):12472-508
Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pôle de Biologie, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France.



Equal access to innovative therapies and precision cancer care.
Nat Rev Clin Oncol 2016 06 22;13(6):385-93. Epub 2016 Mar 22.
Gustave Roussy, 114 rue Edouard Vaillant, F-94805, Villejuif, France and University Paris-SUD, Faculté de Médecine, 63 Rue Gabriel Péri, F-94270 Le Kremlin Bicêtre, France.





OF